Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Bioinformatics -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (15)	8/13/2001 9:05:56 AM
From: nigel bates	Read Replies (1) \| Respond to of 80

Then there's this project - SANTA CLARA, Calif.--(BUSINESS WIRE)--Aug. 9, 2001-- Note: Executives from NCSA, SDSC, Intel, IBM and Qwest will host a teleconference to discuss details of this announcement and answer questions at 1:30 p.m. PDT (4:30 p.m. EDT) on Thursday, Aug. 9. Press and analysts may join the teleconference by dialing 888/202-2422. A full recording of this press conference will be available until Aug. 15 by calling 719/457-0820, passcode 752071. Intel today announced that its Itanium(TM) family of processors will be used to build a distributed scientific computing system expected to be the largest of its kind in the world. The computing system, dubbed the ``TeraGrid,'' is part of a $53 million award by the National Science Foundation (NSF) to four facilities to address complex scientific research by creating a Distributed Terascale Facility (DTF). The TeraGrid will link computers powered by more than 3,300 Intel® Itanium family processors. It will be capable of more than 13.6 trillion calculations per second (13.6 teraflops) and have the ability to store, access and share more than 450 trillion bytes of information. The TeraGrid will be accessible to researchers across the United States so that they can more quickly analyze, simulate and help solve some of the most complex scientific problems. Examples of research areas include molecular modeling for disease detection, cures and drug discovery, automobile crash simulations, research on alternative energy sources and climate and atmospheric simulations for more accurate weather predictions. ``The Itanium processor family is bringing a new level of performance, scalability and lower costs to high-performance computing,'' said Abhi Talwalkar, Intel vice president and assistant general manager, Enterprise Platforms Group. ``Today's NSF award is a major show of support for Itanium technology. All of us at Intel are proud of the role our products play in helping to advance the progress of scientific discovery.'' The system announced today has been dubbed ``TeraGrid'' due to its speed, distributed design and deployment across multiple networked geographic sites. It will achieve ``tera'' performance with its ability to calculate trillions of floating point operations per second (teraflops) and store trillions of bytes (terabytes) of data. The grid is a resource for researchers to mutually access the system and collaborate using shared computing hardware, software and information. Expected to be available in 2002, the TeraGrid is planned to be the most comprehensive distributed scientific computing infrastructure of its kind. It will build upon an existing one-teraflops solution with more than 300 Itanium processors now being deployed at the National Center for Supercomputing Applications (NCSA). The TeraGrid will be based on both Intel's Itanium and ``McKinley'' processors. McKinley is the code name for the second product in Intel's Itanium processor family, due in 2002. The largest portion of the DTF computing power will be at the NCSA at the University of Illinois in Urbana-Champaign. NCSA has three DTF partners which will also deploy Itanium systems: the San Diego Supercomputer Center (SDSC) at the University of California, San Diego; Argonne National Laboratory in suburban Chicago; and the California Institute of Technology in Pasadena. The system will consist of clustered IBM servers running the Linux operating system, and will be connected by a Qwest high-speed optical network. In addition to providing the processors powering the IBM systems, Intel will supply the TeraGrid with key compilers, software, tools and engineering design, and tuning support services. The Itanium architecture design enables breakthrough capabilities in processing terabytes of data at high speeds and processing complex computations. Itanium-based solutions are providing the highest levels of floating-point performance for complex, numerical-intensive applications -- surpassing many of the best RISC-based results and benchmarks to date. The Itanium processor's floating-point engine enables up to 6.4 billion operations per second and includes increased system memory bandwidth.

To: nigel bates who wrote (15)	8/13/2001 11:08:51 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 80

I do TeraFlops. (eom)

To: nigel bates who wrote (15)	9/7/2001 11:17:21 AM
From: nigel bates	Read Replies (1) \| Respond to of 80

Locus Discovery Raises $28 Million in First Close of Series D Equity Financing; Company May Raise up to an Additional $12 Million in a Second Close BLUE BELL, Pa., Sept. 7 /PRNewswire/ -- Locus Discovery Inc., a new computational drug design biopharmaceutical company, announced today the Company has raised $28 million in the first closing of a Series D equity financing. This third round of financing was led by Wanger Asset Management (Acorn Funds), and brings the total funds raised since the Company's founding in September 1999 to $76 million. The Company has the option to raise up to an additional $12 million in a second closing that would bring the total Series D round to $40 million. ING Furman Selz is another new investor in this financing round. Institutions from the previous financing investing in this round include Delphi Ventures, INVESCO Global Health Sciences Fund, Cooper Hill Partners, Origin Capital, Amerindo Investment Advisers, Johnson & Johnson Development Corporation, Prism Venture Partners, Tredegar Investments, and ReqMed Company. ``We are pleased to have this level of interest from the financial community. We plan to undertake chemistry and biology efforts in 20 new drug discovery programs by mid-2002. This funding will allow Locus to pursue these programs as well as continue developing our core computational drug design technology, which we see dramatically changing the traditional drug-discovery paradigm. Locus received a significant increase in valuation from our last financing, which we believe is a strong show of confidence in the current difficult financing environment. We appreciate the support from our investors, and look forward to working with them in continuing to build Locus Discovery,'' commented Nicholas Landekic, President and Chief Executive Officer of Locus Discovery. Locus Discovery's computational technology is a proprietary means of first rapidly and accurately identifying the biologically relevant active binding site of a protein, and then designing small molecule antagonists or agonists of the protein's activity. The technology utilizes proprietary computational procedures and requires knowledge only of the structure of a protein. Unlike traditional research approaches, the Locus Discovery process represents the ability to compress into a few weeks what previously took several years in the drug discovery process, enabling the identification of small molecule drugs substantially faster, with a much higher success rate, and on a much larger scale than has previously been possible. Locus Discovery was organized in September 1999, and is based on technology exclusively licensed from Sarnoff Corporation. The Locus Discovery technology can be used to design therapeutic compounds for many thousands of known protein targets, as well as thousands of new protein targets being identified through genomic research. Some of Locus Discovery's drug design programs include small molecule mimetics of erythropoetin, anti-viral compounds based on a novel target called GP41, and other programs in cancer, infectious diseases, asthma, and neurological and other disorders...